TG Therapeutics, Inc. (TGTX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. TG Therapeutics is a commercial-stage biotechnology company focused on B-cell diseases. Its primary revenue driver is BRIUMVI (ublituximab-xiiy), an FDA-approved treatment for relapsing forms of multiple sclerosis (RMS). The company also holds a commercialization agreement with Neuraxpharm for ex-U.S. markets and is developing a subcutaneous formulation of ublituximab and an allogeneic CAR T therapy (azer-cel).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $204.9 million | $120.9 million |
| Net Income | $19.8 million | $5.1 million |
| Operating Income | $34.8 million | $8.6 million |
| Diluted EPS | $0.12 | $0.03 |
| Cash & Equivalents | $442.2 million | $79.1 million |
| Total Debt (Loan Payable) | $745.1 million | $245.6 million |
| Operating Cash Flow | ($17.9 million) | ($28.7 million) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 69.5% year-over-year, driven by a 68% increase in net product revenue ($201.3M vs. $119.7M). This reflects greater market penetration of BRIUMVI in the U.S. and sales to the ex-U.S. partner, Neuraxpharm.
- Profitability: The company achieved net income of $19.8 million, a significant increase from $5.1 million in Q1 2025. Operating income rose to $34.8 million.
- Debt Restructuring: In March 2026, the company refinanced its $250 million term loan with a new $750 million term loan from Blue Owl Capital. This resulted in a net capital raise of $500 million and a $9.2 million loss on extinguishment of debt recorded in Q1 2026.
- Share Repurchases: The Board increased the share repurchase program authorization from $100 million to $300 million. During Q1 2026, the company repurchased approximately 3.3 million shares for $100.0 million.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose to $88.2 million from $50.3 million, primarily due to increased marketing spend and personnel costs. Cost of revenue increased to $33.5 million, largely due to royalties and manufacturing costs.
Guidance, Outlook, and Risks
- Liquidity: Management anticipates that existing cash, investments ($572.8 million total), and projected revenues will fund operations for more than 12 months.
- Pipeline Updates: The Phase 3 trial for subcutaneous BRIUMVI completed enrollment in April 2026, with topline data expected in late 2026 or Q1 2027. The Phase 1 trial for azer-cel in progressive MS is enrolling.
- Key Risks:
- Commercialization: Dependence on BRIUMVI for revenue; competition in the RMS market; payer reimbursement and pricing pressures.
- Regulatory: Risks associated with maintaining approval for BRIUMVI and obtaining approval for new formulations or indications.
- Supply Chain: Reliance on third-party manufacturers (Samsung Biologics, FUJIFILM Diosynth) and single-source suppliers for raw materials.
- Debt Covenants: The new $750 million facility includes financial covenants and restrictions on dividends and additional indebtedness.
Investor Verification Checklist
- Verify the sustainability of BRIUMVI revenue growth and gross-to-net adjustments (rebates, chargebacks) in future quarters.
- Monitor the impact of the new $750 million debt facility on interest expenses and compliance with leverage covenants.
- Track the progress and topline data release of the subcutaneous BRIUMVI Phase 3 trial (expected late 2026/Q1 2027).
- Assess the execution of the expanded $300 million share repurchase program and its impact on cash reserves.
- Review the status of the ex-U.S. commercialization with Neuraxpharm and royalty recognition.